D-dimer

Overview

D-dimer is a fibrin degradation product formed when cross-linked fibrin is broken down by plasmin during fibrinolysis. Clinically, it is used as a biomarker of coagulation activation and clot turnover, reflecting the presence of recent or ongoing thrombosis, disseminated intravascular coagulation, severe inflammation, and other states associated with increased fibrin formation and breakdown. Because it is generated only after factor XIII-mediated fibrin cross-linking and subsequent fibrinolysis, D-dimer is more specific for intravascular clot formation than fibrinogen alone, although it is not specific for any single disease.

In routine medicine, D-dimer is most often used in the evaluation of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, and it is also studied in systemic lupus erythematosus, COVID-19, trauma, infection, malignancy, and other prothrombotic or inflammatory conditions. In these settings, D-dimer is typically interpreted alongside other coagulation and inflammation markers such as fibrinogen, thrombomodulin, thrombin-antithrombin complex, tissue plasminogen activator-inhibitor complex, C-reactive protein, ferritin, and prothrombin parameters. Elevated levels may indicate thrombotic risk, disease severity, or poor prognosis, but clinical interpretation depends strongly on the underlying context.

Recent Publications Summary

Recent studies continue to position D-dimer as a practical marker of coagulation and fibrinolysis in both diagnostic and prognostic applications. In a multiplex chemiluminescent immunosensor platform designed for simultaneous quantification of five coagulation and fibrinolysis biomarkers—thrombomodulin, thrombin-antithrombin complex, plasmin-α2-plasmin inhibitor complex, tissue plasminogen activator-inhibitor complex, and D-dimer—the biomarker was included as part of a cartridge-based assay aimed at rapid multi-analyte measurement 42578868Aug. This reflects ongoing interest in integrating D-dimer with other hemostatic markers to improve workflow in coagulation assessment.

Several recent clinical studies used D-dimer as a predictive feature in disease modeling. In systemic lupus erythematosus, an explainable machine learning model for in-hospital infection identified D-dimer among nine selected predictors, together with daily prednisone equivalent dose, albumin, hydroxychloroquine use, C-reactive protein, glucose, cystatin C, hemoglobin, and alpha1-globulin 42557059Aug. In the same disease domain, a multicentre trial protocol examining aspirin versus rivaroxaban for prevention of pulmonary embolism and deep vein thrombosis in high-thrombotic-risk patients with systemic lupus erythematosus noted that D-dimer elevation is common in SLE and has been associated with increased risk of venous thromboembolism, although its role in guiding preventive anticoagulation remains uncertain 42161432May.

D-dimer has also been investigated in oncology and critical illness. In acute myeloid leukemia, a study assessed vWF antigen, vWF-ristocetin cofactor, factor VIII, and D-dimer for risk stratification, disease severity, and clinical outcomes 42474591Jul. In severe trauma, a retrospective study examined trajectories of platelet count, fibrinogen, and D-dimer and their value in predicting venous thromboembolism, emphasizing these coagulation indicators as clinically important in trauma care 42207594May. These findings reinforce the use of D-dimer as part of broader hemostatic profiling rather than as a stand-alone diagnostic test.

COVID-19-related studies continued to highlight D-dimer as a marker associated with coagulation disturbance and clinical severity. In a proteomics study of COVID-19, D-dimer and fibrin degradation products were described as existing biomarkers with limited accuracy for stratifying disease severity and predicting long-term clinical outcomes 42323884Jun. Another observational cohort study of severe COVID-19 examined associations between leptin and classical inflammatory and coagulation markers, including D-dimers, prothrombin time, prothrombin activity, international normalized ratio, and activated partial thromboplastin time, to explore inflammation-coagulation cross-talk 42065184May. In a separate retrospective study of hospitalized COVID-19 patients, a combined model incorporating L-lactate dehydrogenase-to-albumin ratio, lymphocyte count, cough, D-dimer, bilateral lung involvement, chest tightness, and shortness of breath achieved good discrimination for oxygen therapy requirement, with an AUC of 0.818, sensitivity of 76.2%, and specificity of 80.0% 42470040Jul. Together, these reports show that D-dimer is still being evaluated as a component of composite models for severity and resource-use prediction in COVID-19.

Beyond classical coagulation testing, D-dimer is being incorporated into multiplexed biosensing and sepsis-oriented diagnostics. A multiplexed sepsis immunosorbent assay based on flower-like CoFe2O4/MoS2 was developed for simultaneous detection of C-reactive protein, serum amyloid A, and D-dimer 42360892Jun. This aligns with broader efforts to combine D-dimer with inflammatory biomarkers such as C-reactive protein and other baseline biomarkers to improve early detection or triage in infection and systemic inflammation.

Overall, the recent literature portrays D-dimer as a clinically versatile biomarker spanning thrombosis, thrombophilia, systemic inflammation, infection, COVID-19, trauma, malignancy, and systemic lupus erythematosus. Across these settings, it is frequently used in combination with fibrinogen complex, proinflammatory cytokine-related markers, ferritin, hemoglobin, albumin, and other laboratory indicators to estimate risk, guide decision-making, or support multiplex assay development 42578868Aug42557059Aug42474591Jul42207594May42323884Jun42161432May42065184May42360892Jun42470040Jul.

What Changes, What Holds

1. D-dimer is moving into integrated multiplex coagulation testing
METHOD Cartridge-based multi-analyte platforms broaden how D-dimer is measured, placing it alongside other hemostatic markers rather than using it as a single standalone result 42578868Aug. This does not change what D-dimer means biologically, but it does sharpen its operational role in rapid coagulation assessment and suggests the field is prioritizing workflow-friendly panels over isolated testing.

2. D-dimer remains a risk marker in systemic lupus erythematosus, but not yet a trigger for prophylaxis
REINFORCES D-dimer continues to fit the baseline view of a nonspecific marker of thrombotic risk and inflammatory burden in SLE 42557059Aug42161432May. The new work supports its use in prediction and modeling, while also leaving the key clinical question unresolved: elevation is common, but whether it should guide preventive anticoagulation remains uncertain.

3. D-dimer adds prognostic value in severe illness only as part of broader hemostatic profiling
REINFORCES Findings in acute myeloid leukemia and severe trauma keep D-dimer in the same lane described by the overview: a marker of clot activation, disease severity, and outcome risk, not a disease-specific diagnostic 42474591Jul42207594May. The main update is practical rather than conceptual: it strengthens the case for combining D-dimer with platelet count, fibrinogen, and other coagulation indices when estimating risk.

4. D-dimer is still useful in COVID-19, but its standalone severity signal is limited
REINFORCES COVID-19 studies continue to place D-dimer within coagulation disturbance and clinical severity assessment, matching the baseline account 42323884Jun42065184May. At the same time, the newer modeling work shows that D-dimer contributes best inside composite predictors of oxygen need rather than as a lone discriminator, which fits the established caution about context-dependent interpretation 42470040Jul.

5. D-dimer is being adopted in sepsis-oriented multiplex assays alongside inflammatory markers
METHOD Biosensor development that measures D-dimer with C-reactive protein and serum amyloid A changes the testing format, not the biological interpretation 42360892Jun. This extends the overview’s point that D-dimer is interpreted with inflammatory markers, but the real advance is analytical: the assay literature is increasingly designing panels for rapid triage and early detection rather than single-marker testing.

6. D-dimer’s present role is broadening across thrombosis, inflammation, infection, and cancer without losing its nonspecificity
REINFORCES Across systemic lupus erythematosus, trauma, leukemia, COVID-19, and sepsis-related work, the recent literature still treats D-dimer as a versatile marker of coagulation activation and fibrinolysis rather than a disease-defining test 42578868Aug42557059Aug42474591Jul42207594May42323884Jun42161432May42065184May42360892Jun42470040Jul. What emerges is breadth of application, not a new mechanism or a reversal of its established clinical meaning.

Overview update candidates: D-dimer’s growing use in multiplex assays and composite prediction models; its continued; uncertain role in guiding prophylaxis in high-risk systemic lupus erythematosus.